LP
IMDX

LMR Partners’s Insight Molecular Diagnostics IMDX Stock Holding History

LMR Partners’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-500
Closed -$3.54K – 1041
2023
Q1 		$3.54K Hold
500
– – ﹤0.01% 998
2022
Q4 		$3.21K Sell
500
-1,073
-68% -$11.8K ﹤0.01% 1083
2022
Q3 		$23K Hold
1,573
– – ﹤0.01% 1151
2022
Q2 		$28K Buy
+1,573
New +$35.8K ﹤0.01% 1212
2022
Q1 		– Sell
-500
Closed -$22K – 1321
2021
Q4 		$22K Hold
500
– – ﹤0.01% 1129
2021
Q3 		$36K Buy
+500
New +$46K ﹤0.01% 968

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LMR Partners's IMDX Position: Q2 2023 in Review

LMR Partners sold out of Insight Molecular Diagnostics (IMDX) in Q2 2023, closing a stake of 500 shares — an estimated $3.54K sold.

LMR Partners first reported a position in IMDX in Q3 2021 and held it in 6 quarters. The position peaked at $36K in Q3 2021. 47 funds tracked by Wall St. Rank hold IMDX as of Q2 2023.

  • LMR Partners reported no remaining Insight Molecular Diagnostics position as of Q2 2023 after selling out during the quarter.
  • LMR Partners sold 500 Insight Molecular Diagnostics shares in Q2 2023, an estimated $3.54K.
  • LMR Partners first reported a position in Insight Molecular Diagnostics in Q3 2021 and held it in 6 quarters.
  • LMR Partners's Insight Molecular Diagnostics position peaked at $36K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.